To our knowledge, TELMA is the first prospective study to evaluate TMB as a biomarker to estimate survival benefit associated with the combination of atezolizumab plus bevacizumab in treatment-naive patients with locally advanced or metastatic nonsquamous NSCLC with no EGFR or ALK genomic alterations. Here, ALK is linked to non-small cell lung carcinoma.